Earnings ·
Upstream Bio reports $39.7M net loss and $261.3M cash, on track to initiate Phase 3 trials in Q1 2027
UPBUpstream Bio, Inc.
Upstream Bio reported second quarter 2026 financial results and clinical updates. The company had cash, cash equivalents, and short-term investments of $261.3 million as of June 30, 2026, sufficient to fund operations through 2027. R&D expenses were $36.1 million and G&A expenses were $7.1 million, resulting in a net loss of $39.7 million compared to a $40.0 million loss in the prior year period. Clinically, Upstream Bio remains on track to initiate Phase 3 trials for severe asthma and CRSwNP in Q1 2027 following End-of-Phase 2 FDA interactions. Enrollment was completed in the Phase 2 VENTURE trial in COPD with 481 participants, with data expected in H2 2027. Upstream Bio is a clinical-stage biotechnology company developing treatments for severe inflammatory respiratory diseases.